[go: up one dir, main page]

EP0714308A4 - METHOD, COMPOSITIONS AND DEVICES FOR THE DELIVERY OF NAKED POLYNUCLEOTIDES THAT ENCODE BIOLOGICALLY ACTIVE PEPTIDES - Google Patents

METHOD, COMPOSITIONS AND DEVICES FOR THE DELIVERY OF NAKED POLYNUCLEOTIDES THAT ENCODE BIOLOGICALLY ACTIVE PEPTIDES

Info

Publication number
EP0714308A4
EP0714308A4 EP94926603A EP94926603A EP0714308A4 EP 0714308 A4 EP0714308 A4 EP 0714308A4 EP 94926603 A EP94926603 A EP 94926603A EP 94926603 A EP94926603 A EP 94926603A EP 0714308 A4 EP0714308 A4 EP 0714308A4
Authority
EP
European Patent Office
Prior art keywords
delivery
compositions
devices
biologically active
active peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94926603A
Other languages
German (de)
French (fr)
Other versions
EP0714308A1 (en
Inventor
Dennis A Carson
Eyal Raz
Meredith L Howell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of EP0714308A1 publication Critical patent/EP0714308A1/en
Publication of EP0714308A4 publication Critical patent/EP0714308A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
EP94926603A 1993-08-26 1994-08-25 METHOD, COMPOSITIONS AND DEVICES FOR THE DELIVERY OF NAKED POLYNUCLEOTIDES THAT ENCODE BIOLOGICALLY ACTIVE PEPTIDES Withdrawn EP0714308A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11244093A 1993-08-26 1993-08-26
US112440 1993-08-26
PCT/US1994/009661 WO1995005853A1 (en) 1993-08-26 1994-08-25 Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides

Publications (2)

Publication Number Publication Date
EP0714308A1 EP0714308A1 (en) 1996-06-05
EP0714308A4 true EP0714308A4 (en) 1998-07-29

Family

ID=22343912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94926603A Withdrawn EP0714308A4 (en) 1993-08-26 1994-08-25 METHOD, COMPOSITIONS AND DEVICES FOR THE DELIVERY OF NAKED POLYNUCLEOTIDES THAT ENCODE BIOLOGICALLY ACTIVE PEPTIDES

Country Status (6)

Country Link
EP (1) EP0714308A4 (en)
JP (2) JPH09501936A (en)
AU (1) AU705889B2 (en)
CA (1) CA2169635C (en)
MX (1) MX9406552A (en)
WO (1) WO1995005853A1 (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503841A (en) 1989-11-16 1993-06-24 デューク ユニバーシティ Particle-mediated transformation of animal tissue cells
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
FR2711670B1 (en) 1993-10-22 1996-01-12 Pasteur Institut Nucleotide vector, composition containing it and vaccine for immunization against hepatitis.
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20020169104A1 (en) 1997-05-01 2002-11-14 Glenn Frank Novel ectoparasite saliva proteins and apparatus to collect such proteins
WO1998045408A2 (en) * 1996-04-10 1998-10-15 Heska Corporation Novel ectoparasite saliva proteins and apparatus to collect such proteins
GB9505777D0 (en) * 1995-03-22 1995-05-10 Zeneca Ltd Process
DE19512142A1 (en) * 1995-03-31 1996-10-02 Immuno Ag Infectious tick-borne encephalitis (TBE) virus cDNA clone, recombinant vaccine derived therefrom and production thereof, and a pharmaceutical product which contains a replicable nucleic acid
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
GB9709900D0 (en) 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
WO1997017063A1 (en) 1995-11-09 1997-05-15 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
AU5507098A (en) * 1995-12-19 1998-03-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Enhancement of dna immunization through the use of cytokines
EP0871747A1 (en) * 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
AU724716B2 (en) * 1996-02-12 2000-09-28 Ml Laboratories Plc Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
AU1865297A (en) * 1996-03-08 1997-09-22 University Of Toronto, The Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
TW480282B (en) 1996-04-24 2002-03-21 Ren Wen Corp Recombinant eucaryotic vector containing allergen gene and use of preventing and treating allergic disease thereof
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (en) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Process for the preparation of nucleic acid constructs
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
KR20080009171A (en) * 1997-08-13 2008-01-24 더 유에이비 리서치 파운데이션 Vaccination by Topical Application of Gene Vectors
JP4663113B2 (en) 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO1999036563A1 (en) * 1998-01-14 1999-07-22 Emed Corporation Electrically mediated cellular expression
CA2321837C (en) * 1998-02-03 2011-08-16 Inex Pharmaceuticals Corporation Systemic delivery of serum stable plasmid lipid particles for cancer therapy
DE69935507T2 (en) 1998-04-03 2007-12-06 University Of Iowa Research Foundation METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM BY IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINES
JP4540845B2 (en) * 1998-04-20 2010-09-08 トーレイ パインズ インスティテュート フォー モレキュラー スタディーズ Local immune stimulation induces Langerhans cell migration
AU4186899A (en) 1998-05-12 1999-11-29 Susan C. Bock Human antithrombin iiis and methods related thereto
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1163024B1 (en) * 1999-01-28 2003-12-17 Cyto Pulse Sciences, Inc. Delivery of macromolecules into cells
US6335182B1 (en) * 1999-03-16 2002-01-01 Aventis Pasteur Limited Recombinant Haemophilus influenzae adhesin proteins
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
CA2410371C (en) 2000-06-22 2015-11-17 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
WO2002055559A1 (en) * 2001-01-15 2002-07-18 Keryos Spa Dna vaccines expressing hypervariable vh-cdr3 idiotipic determinants
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US7776321B2 (en) 2001-09-26 2010-08-17 Mayo Foundation For Medical Education And Research Mutable vaccines
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
GB0201736D0 (en) * 2002-01-25 2002-03-13 Glaxo Group Ltd DNA dosage forms
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1530629B1 (en) 2002-05-31 2011-08-31 The University of Utah Research Foundation Variants of antithrombin iii
US6946186B2 (en) 2002-08-24 2005-09-20 International Paper Co. Uncoated facestock for adhesive-backed labels
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2555989A1 (en) 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
EA013752B1 (en) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
JP2008528508A (en) * 2005-01-21 2008-07-31 イントロジェン・セラピューティクス，インコーポレイテッド Topical administration that allows for sustained exposure of target cells to therapeutic and prophylactic nucleic acids
CN101171033A (en) 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 Vaccines comprising oligonucleotides with an immunostimulatory sequence ISS: wherein the ISS is conjugated to an antigen and stabilized by buffer conditions and other excipients
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2035448A4 (en) 2006-06-01 2010-11-03 Elan Pharm Inc NEUROACTIVE FRAGMENTS OF APP
ES2546863T3 (en) 2007-02-23 2015-09-29 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP5558834B2 (en) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー Prevention and treatment of synucleinopathies and amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (en) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanized anti-beta antibodies
EP3241846B1 (en) 2007-10-04 2022-02-23 ZymoGenetics, Inc. B7 family member zb7h6 and related compositions and methods
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
EA028356B1 (en) 2007-12-28 2017-11-30 Протена Байосайенсиз Лимитед Treatment and prophylaxis of amyloidosis
AU2009259959A1 (en) 2008-06-20 2009-12-23 Wyeth Llc Compositions and methods of use of ORF1358 from beta-hemolytic streptococcal strains
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2008363648B9 (en) * 2008-10-31 2013-08-22 Tremrx, Inc. Vaccination with poxvirus vectors via mechanical epidermal disruption
BR112012031329A2 (en) 2010-06-09 2016-10-11 Zymogenetics Inc vstm3 dimeric fusion proteins and related compositions and methods
BR112014006376B1 (en) 2011-09-19 2021-07-27 Axon Neuroscience Se ISOLATED ANTIBODY THAT LINKS TO ONE OR MORE TAU EPITOPES, NUCLEIC ACID, VECTOR, PHARMACEUTICAL COMPOSITION, ARTICLE OF MANUFACTURING, MEDICAL DEVICE, IN VITRO METHOD FOR DIAGNOSING OR TRIATING AN INDIVIDUAL FOR THE PRESENCE OF A TAUTION OR USE OF ALZ OF SUCH ANTIBODY
KR101445560B1 (en) 2012-05-10 2014-09-29 한국수력원자력 주식회사 Detection Method of Sensitive Genes for Low-Dose-Rate Radiation and Genes Detected by This Method
JP5917626B2 (en) * 2014-07-28 2016-05-18 トレムアールエックス， インコーポレイテッド Vaccination with poxvirus vectors via mechanical epidermal destruction

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3596660A (en) * 1969-05-12 1971-08-03 Illinois Tool Works Injection device
US4657901A (en) * 1983-09-07 1987-04-14 Sheiseido Company, Ltd. Pharmaceutical composition
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
WO1991018013A1 (en) * 1990-05-24 1991-11-28 Research Corporation Technologies, Inc. Synthetic senescent cell antigen
GB2258618A (en) * 1991-08-05 1993-02-17 Zenith Technology Corp Ltd Fluid medicament applicator
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3596660A (en) * 1969-05-12 1971-08-03 Illinois Tool Works Injection device
US4657901A (en) * 1983-09-07 1987-04-14 Sheiseido Company, Ltd. Pharmaceutical composition
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
WO1991018013A1 (en) * 1990-05-24 1991-11-28 Research Corporation Technologies, Inc. Synthetic senescent cell antigen
GB2258618A (en) * 1991-08-05 1993-02-17 Zenith Technology Corp Ltd Fluid medicament applicator
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEEST VAN DER R ET AL: "IONTOPHORESIS: A TRANSDERMAL DELIVERY STRATEGY FOR ANTISENSE OLIGONUCLEOTIDE DRUGS ?", PHARMACEUTICAL RESEARCH, vol. 9, no. 10, October 1992 (1992-10-01), pages S-67, XP000655154 *
See also references of WO9505853A1 *

Also Published As

Publication number Publication date
EP0714308A1 (en) 1996-06-05
WO1995005853A1 (en) 1995-03-02
CA2169635A1 (en) 1995-03-02
MX9406552A (en) 1997-02-28
CA2169635C (en) 2002-11-12
JP2004331668A (en) 2004-11-25
AU7639194A (en) 1995-03-21
JPH09501936A (en) 1997-02-25
AU705889B2 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
EP0714308A4 (en) METHOD, COMPOSITIONS AND DEVICES FOR THE DELIVERY OF NAKED POLYNUCLEOTIDES THAT ENCODE BIOLOGICALLY ACTIVE PEPTIDES
FR2683577B1 (en) MODULAR LANDSCAPING DEVICES AND STRUCTURES.
PL297747A1 (en) Prolonged action pharmaceutical dosage forms
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
TJ313B (en) Erythromycin's dervatives and pharmaceutical composition on their basis
IL118369A (en) (2R)-1-¬3,5-bis(trifluoromethyl)benzoyl¾-2-(1H-indol-3-YL-methyl)-4-¬N-(4-methyl-1-piperazinyl)carbamoylmethyl¾-piperazine processes for its preparation and pharmaceutical compositions containing same
FR2600494B1 (en) SYNERGY AGENT FOR A BIOCIDE, BIOCIDE COMPOSITION CONTAINING THE SAME, AND METHOD FOR REINFORCING A BIOCIDE
FR2680109B1 (en) COMPOSITION FOR THE SUSTAINED AND CONTROLLED RELEASE AND CONTROL OF A PEPTIDE DRUG SUBSTANCE AND PROCESS FOR ITS PREPARATION.
DE69228847D1 (en) Fluid delivery and evaporation system
OA09749A (en) "1-aryl-5- (substituted alkylideneimino) -pyrazoles pesticides, processes for their preparation, compositions containing them and their use".
HU9200171D0 (en) "pour-on"pesticide
EP0667139A4 (en) Device for enhancing human work fitness: "kuznetsov applicator".
FR2695297B1 (en) Disinfectant agent composition.
FR2686251B1 (en) COMPOSITION FOR THE HEALING OF A WOUND.
IL101482A0 (en) Substituted 2',3'-dideoxy-5-trifluoromethyluridines,and pharmaceutical compositions containing them
FR2677250B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DISOD ADENOSINE-5-TRIPHOSPHATE.
GB9410140D0 (en) Medicinal fluid composition for trees
EP0653208A3 (en) Substance P antagonists for the treatment and prevention of solar erythema.
FR2684299B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DISENTIC ADENOSINE-5-TRIPHOSPHATE AND AMILORIDE.
ZA934424B (en) Pharmaceutical compositions containing amidines and novel amidines.
HU9500523D0 (en) 1,2,4-dithiazolium iodines and their use pesticides
FR2690545B1 (en) MODULAR ARCHITECTURE DRESSING.
GB9218709D0 (en) Biologically active health formulation
ITRM920077A1 (en) TIE PACKING DEVICE.
ZW17793A1 (en) "Fungicidal agents"

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/87

A4 Supplementary search report drawn up and despatched

Effective date: 19980609

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020131

17Q First examination report despatched

Effective date: 20020131

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/54 20060101AFI20080304BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080716